skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Pegylated Liposomal Mitomycin C Lipid-based Prodrug (Code C103276)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Pegylated Liposomal Mitomycin C Lipid-based Prodrug

Definition: A pegylated liposomal formulation comprised of a lipophilic prodrug of the antineoplastic antibiotic mitomycin C containing a cleavable disulfide bond (PL-MLP), with potential antineoplastic activity. Upon administration of the pegylated liposomal mitomycin C lipid-based prodrug, the MLP moiety becomes activated upon thiolysis at the tumor site, thereby releasing mitomycin C. Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. The thiolytic environment and upregulated expression of thioredoxins at the tumor site allow for the activation and release of mitomycin C. This prodrug formulation allows for greater circulation time, less systemic toxicity and increased accumulation of mitomycin C at the tumor site.

Label: Pegylated Liposomal Mitomycin C Lipid-based Prodrug

NCI Thesaurus Code: C103276 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL438127  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Pegylated Liposomal Mitomycin C Lipid-based Prodrug

External Source Codes: 
PDQ Closed Trial Search ID 741900
PDQ Open Trial Search ID 741900 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C103276
Semantic_Type Antibiotic
Semantic_Type Organic Chemical

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom